Oral Galactose as a Substrate for Post-Exercise Skeletal Muscle Glycogen Repletion in Individuals With Type 1 Diabetes

Sponsor
University of Aarhus
Study ID
NCT07774780
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • galactose — DIETARY_SUPPLEMENT
    Participants undergo two experimental conditions in a randomized crossover design. In one condition, participants ingest 30 g of galactose, whereas in the other condition, they ingest 30 g of galactose combined with 30 g of glucose. The order of the conditions is randomized across participants.

Study Details

This Ph.D. project investigates whether orally ingested galactose can be taken up by skeletal muscle and the heart in response to exercise or hyperinsulinemia, and whether it may serve as a viable nutritional strategy for individuals with type 1 diabetes (T1D). Although exercise provides significant health benefits for people with T1D, it is often associated with substantial glucose fluctuations and an increased risk of hypoglycemia. Conventional carbohydrate strategies based on glucose may further exacerbate glycemic instability due to the rapid increase in blood glucose levels. In contrast, galactose is metabolized more slowly and may therefore provide a more stable energy source during and after exercise. Previous research has demonstrated that intravenously administered galactose is taken up by human skeletal muscle, with uptake increasing during exercise, suggesting a mechanism that may be at least partly insulin-independent. Building on these findings, this project aims to determine whether similar uptake occurs when galactose is ingested orally. This study uses a randomized controlled design and applies non-invasive 18F-FDGal PET imaging to quantify galactose uptake in skeletal muscle and cardiac tissue. The findings may contribute to improving dietary recommendations for individuals with T1D, particularly in relation to maintaining stable blood glucose levels during and after physical activity.

Key Dates

First listed
Aug 19, 2026
Start date
Feb 1, 2027
Status verified
Aug 2026
Primary completion
Sep 30, 2028
Completion
May 31, 2029

Study Design

Enrollment
16 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION

Arms

  • Experimental: Galactose
    The patient will orally ingest 30 g of galactose.
  • Active Comparator: Galactose + Glucose
    The patient will orally ingest 30 g of galactose and 30 g of glucose.

Primary Outcome Measure

Skeletal muscle galactose uptake rate (μmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal) [ Time Frame: Measurement will be made on each of the two study days ]

Central Contacts

Find similar trials

Nationwide
Type 1 diabetes trialsEndocrinology trials

Related Studies